No Panel Needed To Expand Impella Into Cardiogenic Shock, Abiomed Says
This article was originally published in The Gray Sheet
Executive Summary
Abiomed and FDA have agreed to an indication that would allow the firm to market its percutaneous Impella pumps for circulatory support of patients in cardiogenic shock following acute myocardial infarction or cardiac surgery, and no advisory panel will be needed before FDA makes an approval decision, the company says.
You may also be interested in...
Impella 2.5 PMA Gives Abiomed Big Growth Potential For High-Risk PCIs
The approval, the first for a percutaneous hemodynamic support device, frees Abiomed's hand to market the miniature blood pump to a relatively broad patient population, analysts note.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.